A new amyloid β variant favoring oligomerization in Alzheimer's‐type dementia

@article{Tomiyama2008ANA,
  title={A new amyloid $\beta$ variant favoring oligomerization in Alzheimer's‐type dementia},
  author={Takami Tomiyama and Tetsu Nagata and Hiroyuki Shimada and Rie Teraoka and Akiko Fukushima and Hyoue Kanemitsu and Hiroshi Takuma and Ryozo Kuwano and Masaki Imagawa and Suzuka Ataka and Yasuhiro Wada and Eito Yoshioka and Tomoyuki Nishizaki and Yasuyoshi Watanabe and Hiroshi Mori},
  journal={Annals of Neurology},
  year={2008},
  volume={63}
}
Soluble oligomers of amyloid β (Aβ), rather than amyloid fibrils, have been proposed to initiate synaptic and cognitive dysfunction in Alzheimer's disease (AD). However, there is no direct evidence in humans that this mechanism can cause AD. Here, we report a novel amyloid precursor protein (APP) mutation that may provide evidence to address this question. 
Apolipoprotein E, amyloid-ß clearance and therapeutic opportunities in Alzheimer's disease
  • Adam Kline
  • Biology, Psychology
    Alzheimer's Research & Therapy
  • 2012
TLDR
The key interactions of apoE and Aß pathology, the current progress of preclinical animal models and the caveats of existing therapeutic approaches targeting apo E are discussed.
The toxic Aβ oligomer and Alzheimer's disease: an emperor in need of clothes
TLDR
The evidence supporting toxic Aβ oligomers as drivers of neurodegeneration is reviewed and some suggestions that might facilitate progress are made to facilitate progress in this complex field.
Aβ Oligomer-Induced Synapse Degeneration in Alzheimer’s Disease
TLDR
This brief review of the synaptotoxic effects of Aβ oligomers focuses on the neuronal properties governing oligomer targeting and toxicity—especially with respect to binding sites and mechanisms of binding.
Aß Monomer, Oligomer and Fibril in Alzheimer’s Disease
TLDR
This chapter identifies a novel APP mutation (E693delta; referred to as the Osaka mutation) in a pedigree with probable AD, resulting in a variant Aβ lacking glutamate at position 22 that showed a unique and enhanced oligomerization activity without fibrillization.
Amyloid tracers binding sites in autosomal dominant and sporadic Alzheimer's disease
Cerebral amyloidosis: amyloid subunits, mutants and phenotypes
TLDR
The familial forms reviewed herein, although infrequent, provide unique paradigms to examine the role of amyloids in the mechanism of disease pathogenesis and to dissect the link between vascular and parenchymal amyloid deposition and their differential contribution to neurodegeneration.
Toxic oligomer species of amyloid-β in Alzheimer's disease, a timing issue.
TLDR
This review integrated recent findings and extrapolated emerging hypotheses derived from these studies with the hope to provide a clarified view on the putative role of endogenous Aβ oligomers in AD, with a particular emphasis on the timing at which these soluble species might act in the aging and diseased brain.
Synaptotoxic amyloid-β oligomers: a molecular basis for the cause, diagnosis, and treatment of Alzheimer's disease?
  • W. Klein
  • Biology
    Journal of Alzheimer's disease : JAD
  • 2013
TLDR
Insight over the past five years raise hopes that new approaches targeting Aβ oligomers could finally bring disease-modifying therapeutics to Alzheimer's disease.
Alzheimer's disease: synaptic dysfunction and Aβ
TLDR
The evidence that non-fibrillar soluble forms of Aβ are mediators of synaptic compromise is reviewed and the possible mechanisms of A β synaptotoxicity and potential targets for therapeutic intervention are discussed.
...
...

References

SHOWING 1-10 OF 42 REFERENCES
Alzheimer's Disease Is a Synaptic Failure
TLDR
Mounting evidence suggests that this syndrome begins with subtle alterations of hippocampal synaptic efficacy prior to frank neuronal degeneration, and that the synaptic dysfunction is caused by diffusible oligomeric assemblies of the amyloid β protein.
Natural oligomers of the amyloid-β protein specifically disrupt cognitive function
TLDR
The biochemical isolation of discrete amyloid-β moieties with pathophysiological properties sets the stage for a new approach to studying the molecular mechanisms of cognitive impairment in Alzheimer disease and related neurodegenerative disorders.
A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease.
TLDR
Direct sequencing of DNA from a family with autopsy-proven Alzheimer's disease revealed a single amino acid substitution (Phe for Val) in the transmembrane domain of the amyloid precursor protein, which may be the inherited factor causing both amyloids fibril formation and dementia.
A specific amyloid-β protein assembly in the brain impairs memory
TLDR
It is found that memory deficits in middle-aged Tg2576 mice are caused by the extracellular accumulation of a 56-kDa soluble amyloid-β assembly, which is proposed to be Aβ*56 (Aβ star 56), which may contribute to cognitive deficits associated with Alzheimer's disease.
Imaging of amyloid burden and distribution in cerebral amyloid angiopathy
TLDR
It is hypothesized that amyloid deposition would be observed with PiB in CAA, and based on the occipitals predilection of CAA pathology and associated hemorrhages, that specific PiB retention would be disproportionately greater in occipital lobes.
Rifampicin prevents the aggregation and neurotoxicity of amyloid beta protein in vitro.
The aggregation and cerebral deposition of amyloid beta protein (A beta), which is a major component of senile plaques in Alzheimer's disease (AD) brains, is believed to be involved in the
Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type.
TLDR
Cloning and sequencing of the two exons that encode the amyloid protein from two patients with this amyloidsosis revealed a cytosine-to-guanine transversion, a mutation that caused a single amino acid substitution (glutamine instead of glutamic acid) at position 22 of the ameloid protein.
Deposition of beta-amyloid subtypes 40 and 42 differentiates dementia with Lewy bodies from Alzheimer disease.
TLDR
The Abeta plaques were more numerous in patients with DLB than persons with normal aging, but the plaque sub types were similar, and the relative proportion of the 2 Abeta plaque subtypes in DLB is distinguishable from that in AD.
...
...